Gout mostly hits men, and the evidence says treat the urate, not just the flares

Gout is overwhelmingly a men's disease, and its cause is not bad luck or rich food alone but a measurable excess of uric acid in the blood that crystallises in joints [s2]. The evidence-based response is to lower that urate to a target and keep it there with a daily drug, not merely to treat each agonising flare as it comes — yet only about a third of people with gout are on such treatment [s2].

In the most recent US national survey, gout affected 3.9% of adults — roughly 9.2 million people — but the burden was split sharply by sex: 5.2% of men (5.9 million) against 2.7% of women (3.3 million) [s2]. The upstream abnormality, high serum urate, was common in both: hyperuricaemia, defined as urate above 7.0 mg/dl in men and 5.7 mg/dl in women, affected about 20% of each [s2]. Most people with high urate never get gout, but sustained high levels are the necessary condition for it, which is why the number on the blood test, not the pain, is what treatment is built around.

What gout actually is

Uric acid is the end product of breaking down purines, molecules found in the body's own cells and in food. When blood levels stay high enough for long enough, urate forms needle-like crystals in and around joints — classically the base of the big toe — and the immune reaction to those crystals produces the sudden, severe attacks that define gout. Left unchecked, crystals accumulate into visible lumps called tophi and can erode bone. The same crystals can also form in the urinary tract, one route to the uric-acid variety of kidney stones.

Treat the cause, to a target

The 2020 American College of Rheumatology guideline, built from a systematic review graded by GRADE methodology, issued 42 recommendations, 16 of them strong [s1]. Its spine is a "treat-to-target" strategy: start urate-lowering therapy, then titrate the dose against repeat blood tests until serum urate sits below 6 mg/dl, and keep it there [s1]. The guideline strongly recommends starting that therapy for anyone with tophi, joint damage visible on imaging, or frequent flares [s1].

On which drug, the guideline is unambiguous: allopurinol is the strongly preferred first-line agent for all patients, including those with moderate-to-severe chronic kidney disease [s1]. It should be started low — 100 mg a day or less, and lower still in kidney disease — and increased gradually, both to reach the target safely and to reduce the risk of a rare severe skin reaction [s1]. Because urate-lowering can paradoxically trigger flares as crystals dissolve, the guideline strongly recommends taking an anti-inflammatory — colchicine, a non-steroidal anti-inflammatory drug, or a glucocorticoid — as prophylaxis for at least three to six months when treatment begins [s1]. For an acute flare, those same three drug classes are the strongly recommended options [s1].

The safety question that reshaped prescribing

The second-line urate-lowerer, febuxostat, has been the subject of two large cardiovascular safety trials that reached different-sounding conclusions — a useful case study in reading trial evidence. The CARES trial randomised 6,190 patients who had both gout and established cardiovascular disease and followed them for a median of 32 months [s3]. Febuxostat was non-inferior to allopurinol for the main combined heart endpoint (events in 10.8% versus 10.4%; hazard ratio 1.03) — but deaths were higher on febuxostat, both from any cause (hazard ratio 1.22, 95% CI 1.01 to 1.47) and from cardiovascular causes (hazard ratio 1.34, 95% CI 1.03 to 1.73) [s3]. That result drove a boxed warning and cautious guideline language.

The later FAST trial, in 6,128 patients aged 60 or older with a cardiovascular risk factor — 85.3% of them men — did not reproduce the mortality signal [s4]. Febuxostat was again non-inferior for the primary heart endpoint (hazard ratio 0.85, 95% CI 0.70 to 1.03), and deaths were if anything fewer on febuxostat (7.2%) than on allopurinol (8.6%); the authors concluded long-term febuxostat carried no increased risk of death or serious harm versus allopurinol [s4]. The honest summary is that the two trials disagree, that both nonetheless confirm allopurinol as the sensible default, and that CARES's very high dropout rate complicates its mortality finding.

What this means, plainly

The gap here is not in the science but in its use. Effective, cheap, decades-old treatment exists, its target is a single number on a blood test, and the guideline backing it is strong — yet the survey found only 33% of gout patients on urate-lowering therapy [s2]. The disease is often managed as a series of painful episodes rather than the chronic metabolic condition it is. One caution the evidence does support: lowering urate treats gout, but it is not a proven kidney-protector on its own, as randomised trials of urate-lowering for kidney disease found no benefit — and colchicine's separate, much-debated role in preventing heart attacks is a different question from its use in gout. For gout itself, the target and the first-line drug are settled; the failure is in reaching them.